Pill Identification & Overview
A white, round tablet debossed with “AN 627” on one side and blank on the reverse is Tramadol Hydrochloride 50 mg (immediate-release).
Characteristic – Specification
- Active Ingredient – Tramadol Hydrochloride
- Strength – 50 mg
- Drug Class – Synthetic opioid analgesic / Central nervous system (CNS) agent
- Color & Shape – White, round, biconvex tablet
- Imprint / Markings – “AN 627” on one side; plain on the reverse
- Manufacturer – Amneal Pharmaceuticals
- Controlled Status – Schedule IV (C-IV) Controlled Substance (Rx-only)
Mechanism of Action (Pharmacology)
Tramadol provides analgesia through a distinct dual mechanism of action:
- Receptor Agonism: Tramadol and its active primary metabolite, desmethyltramadol (M1) (produced via hepatic CYP2D6 metabolism), bind to opioid receptors in the central nervous system. The M1 metabolite exhibits a significantly higher affinity for opioid receptors than the parent drug, inhibiting ascending pain pathways.
- Inhibition of Monoamine Reuptake: Tramadol inhibits the neuronal reuptake of serotonin and norepinephrine . This enhances inhibitory descending pain signaling pathways in the spinal cord, supplementing the opioid-mediated analgesic effect.
Indications & Dosage Guidelines
Therapeutic Indications
- Moderate to Moderately Severe Pain: Indicated for acute post-surgical pain, injury-related pain, and chronic conditions such as osteoarthritis or severe musculoskeletal pain when non-opioid analgesics are inadequate.
Typical Adult Dosage (Immediate-Release)
- Initial / Acute Pain Dose: 25 mg to 50 mg orally every 4 to 6 hours as needed for pain.
- Titration: May increase by 50 mg every 3 days as tolerated to reach optimal pain relief.
- Maximum Daily Dose: 400 mg per day (8 tablets of 50 mg) for adults with normal hepatic and renal function.
- Special Populations:
- Elderly (≥ 75 years): Maximum daily dose should generally not exceed 300 mg due to reduced clearance.
- Renal/Hepatic Impairment: Dosing intervals may need to be extended (e.g., every 12 hours) with lower maximum daily thresholds.
Side Effects Profile
Common Side Effects
- Dizziness, vertigo, and lightheadedness
- Nausea, vomiting, and abdominal discomfort
- Drowsiness, sedation, and fatigue
- Constipation
- Headache
- Diaphoresis (excessive sweating)
- Dry mouth (xerostomia)
Serious Adverse Reactions
- Respiratory Depression: Slowed, shallow, or irregular breathing.
- Seizures: Reduced seizure threshold, which can cause convulsions even at recommended doses.
- Serotonin Syndrome: Potentially fatal excess serotonin accumulation.
- Severe Hypotension / Syncope: Precipitous drops in blood pressure upon standing.
- Adrenal Insufficiency: Long-term opioid use can lead to reversible impairment of cortisol production.
Precautions & Drug Interactions
- Antidepressants (SSRIs, SNRIs, TCAs, MAOIs): Combining tramadol with serotonergic medications markedly increases the risk of serotonin syndrome and lowers the seizure threshold. Concomitant use with MAO inhibitors is strictly contraindicated within 14 days.
- CYP2D6 & CYP3A4 Interactions:
- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) reduce conversion to the potent M1 metabolite, altering analgesic response and raising tramadol levels.
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) decrease overall clearance.
- Seizure Risk Factors: Tramadol should be avoided or used with extreme caution in patients with a history of epilepsy, head trauma, or metabolic disorders predisposing to seizures.
- Physical Dependence & Tapering: Abrupt cessation after extended use can trigger a complex withdrawal syndrome combining classic opioid withdrawal (aches, diarrhea, agitation) with atypical monoamine withdrawal (severe anxiety, panic attacks, paresthesias, tremors).
Boxed Warnings & Safety Highlights
FDA Black Box Warnings
- Addiction, Abuse, and Misuse: Tramadol exposes patients to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or dose escalation.
- Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can result in a fatal overdose.
- Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use of opioids with benzodiazepines or alcohol may result in profound sedation, respiratory depression, coma, and death.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can cause life-threatening withdrawal symptoms in the newborn.
- Contraindications in Pediatric Populations: Contraindicated in all children under 12 years of age, and in post-operative management in pediatric patients undergoing tonsillectomy and/or adenoidectomy due to variable CYP2D6 ultra-rapid metabolism risking fatal respiratory depression.